Prof Noel Clarke speaks to ecancer about the timing of radiotherapy after radical prostatectomy at the ESMO Congress 2023.

The study presented the concept that adjuvant radiotherapy for patients at increased risk of cancer relapse following radical prostatectomy failed to improve key clinical endpoints, but induced significant side effects when compared to the initiation of early salvage radiotherapy in cases of biochemical progression.

The primary outcome data from the phase III RADICALS-RT trial confirm initial results that did not support routine administration of adjuvant radiotherapy after surgery.